Clinical Trials List
Protocol NumberCYTB323K12201
Active
2024-01-02 - 2030-01-02
Phase II
Recruiting1
ICD-10M34.0
Progressive systemic sclerosis
ICD-10M34.1
CR(E)ST syndrome
ICD-10M34.2
Systemic sclerosis induced by drug and chemical
ICD-10M34.89
Other systemic sclerosis
ICD-10M34.9
Systemic sclerosis, unspecified
ICD-9710.1
Systemic sclerosis
xxxxxx
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
xxxxxx
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Principal Investigator
WEN-NAN HUANG
Co-Principal Investigator
- 高宗楙 Division of General Internal Medicine
- 陳彥如
- 賴國隆
- 許鶴忀
- Huey-En Tzeng
- 謝佳偉
- Yi-Ming Chen
- 廖育婉
- 顏在弘
- Kuan-Der Lee Division of General Internal Medicine
- HSIN-HUA CHEN
- CHIH-HUNG LAI
- 洪維廷 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
xxxxxx
Objectives
xxxxxx
Test Drug
xxxxxx
Active Ingredient
YTB323
Dosage Form
246
Dosage
CAR-positive viable T cells
Endpoints
xxxxxx
Inclution Criteria
xxxxxx
Exclusion Criteria
xxxxxx
The Estimated Number of Participants
-
Taiwan
2 participants
-
Global
96 participants
